FIELD: medicine.
SUBSTANCE: tissue is homogenised in a buffer and centrifuged at 105000 g for 60-90 min at 0-4°C to produce a cytoplasmic fraction which is then incubated with 10 mM of phosphocreatine and 10 mcg/ml of phosphocreatine kinase for 25-45 minutes at 35°C. Cytoplasmic fraction proteins are divided by ammonium sulphate at three stages, at the first stage ammonium sulphate is added to 38% of saturation and centrifuged to isolate a precipitate containing a 26S-proteasome pool, at the second stage, a supernatant is added with ammonium sulphate to 42 % of saturation and centrifuged to isolate a precipitate containing ballast proteins, at the third stage to the supernatant is added with ammonium sulphate to 70 % of saturation and centrifuged to isolate a precipitate containing a 20S-npoteasome pool. Ammonium sulphate is added in portions during 20 min on a magnetic stirrer and further mixed for 20 minutes.
EFFECT: invention allows dividing native 26S- and 20S-proteasomes and isolating them in those amounts they exist in living cells, with preserving at most an undamaged 26S-proteasome structure.
3 cl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PRODUCTION OF IMMUNOGENIC PREPARATIONS USING PROTEASOME SYSTEM USEFUL IN SCREENING OF AGENTS FOR VIRAL INFECTION PROPHYLAXIS | 2004 |
|
RU2279290C2 |
INTRAOPERATIVE DIAGNOSTIC TECHNIQUE FOR THYROID CARCINOMA | 2013 |
|
RU2521239C1 |
METHOD FOR PRODUCING VIABLE HETEROGENOUS SKIN CELL POPULATION | 2012 |
|
RU2502999C1 |
METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
METHOD FOR PREDICTION OF CLINICAL OUTCOME OF MUSCULO-INVASIVE BLADDER CANCER FOLLOWING COMBINATION THERAPY | 2012 |
|
RU2538632C2 |
METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
METHOD OF IDENTIFYING REGULATOR SHORT-LIVED PROTEINS IN HUMAN PROTEOME INVOLVED IN SPECIFIC MODULATION OF CYTOTOXIC EFFECT | 2012 |
|
RU2590700C2 |
METHOD FOR PREDICTION OF DEVELOPING LYMPHOGENIC METASTASES IN SQUAMOUS CELL CARCINOMA OF HEAD AND NECK FOLLOWING COMBINATION THERAPY | 2013 |
|
RU2527338C1 |
SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
α-KETOAMIDE INHIBITORS OF 20S-PROTEASOME | 1999 |
|
RU2192429C2 |
Authors
Dates
2011-08-27—Published
2010-05-14—Filed